These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 19293550)

  • 1. Intensive chemotherapy for a patient with primary cutaneous diffuse large B-cell lymphoma with Burkitt-like morphology.
    Okudaira T; Nagasaki A; Miyagi T; Taira T; Ohshima K; Takasu N
    Intern Med; 2009; 48(6):475-8. PubMed ID: 19293550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL.
    Maruyama D; Watanabe T; Maeshima AM; Nomoto J; Taniguchi H; Azuma T; Mori M; Munakata W; Kim SW; Kobayashi Y; Matsuno Y; Tobinai K
    Int J Hematol; 2010 Dec; 92(5):732-43. PubMed ID: 21120644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CODOX-M/IVAC (NCI 89-C-41) in children and adolescents with Burkitt's leukemia/lymphoma and large B-cell lymphomas: a 15-year monocentric experience.
    Moleti ML; Testi AM; Giona F; Malandruccolo L; Pescarmona E; Martino P; Paoloni F; Barberi W; Palumbo G; Mandelli F; Foa R
    Leuk Lymphoma; 2007 Mar; 48(3):551-9. PubMed ID: 17454598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma.
    Wang ES; Straus DJ; Teruya-Feldstein J; Qin J; Portlock C; Moskowitz C; Goy A; Hedrick E; Zelenetz AD; Noy A
    Cancer; 2003 Sep; 98(6):1196-205. PubMed ID: 12973843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma: report of a case in the oral cavity.
    Jaradat JM; Potluri A; Bilodeau EA
    Indian J Dent Res; 2013; 24(3):384-6. PubMed ID: 24025890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study.
    Xiao J; Du S; Dai G; Gao G; Yang D; Zhao H
    Sci Rep; 2017 May; 7(1):1905. PubMed ID: 28507339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study.
    Mead GM; Sydes MR; Walewski J; Grigg A; Hatton CS; Pescosta N; Guarnaccia C; Lewis MS; McKendrick J; Stenning SP; Wright D;
    Ann Oncol; 2002 Aug; 13(8):1264-74. PubMed ID: 12181251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of Burkitt lymphoma and Burkitt-like lymphoma].
    Maruyama D
    Rinsho Ketsueki; 2011 Oct; 52(10):1645-54. PubMed ID: 21971242
    [No Abstract]   [Full Text] [Related]  

  • 9. High-grade mature B-cell lymphoma with Burkitt-like morphology: results of a clinicopathological study of 72 Japanese patients.
    Nomura Y; Karube K; Suzuki R; Ying G; Takeshita M; Hirose S; Nakamura S; Yoshino T; Kikuchi M; Ohshima K
    Cancer Sci; 2008 Feb; 99(2):246-52. PubMed ID: 18271922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifiable' highly aggressive B-cell lymphoma.
    Corazzelli G; Frigeri F; Russo F; Frairia C; Arcamone M; Esposito G; De Chiara A; Morelli E; Capobianco G; Becchimanzi C; Volzone F; Saggese M; Marcacci G; De Filippi R; Vitolo U; Pinto A
    Br J Haematol; 2012 Jan; 156(2):234-44. PubMed ID: 22098541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AIDS-associated Burkitt or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effective.
    Hoffmann C; Wolf E; Wyen C; Fätkenheuer G; Van Lunzen J; Stellbrink HJ; Stoehr A; Plettenberg A; Jaeger H; Noppeney R; Hentrich M; Goekbuget N; Hoelzer D; Horst HA
    Leuk Lymphoma; 2006 Sep; 47(9):1872-80. PubMed ID: 17065000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes of AIDS-related Burkitt lymphoma: a multi-institution retrospective survey in Japan.
    Kojima Y; Hagiwara S; Uehira T; Ajisawa A; Kitanaka A; Tanuma J; Okada S; Nagai H
    Jpn J Clin Oncol; 2014 Apr; 44(4):318-23. PubMed ID: 24558129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.
    Lin P; Dickason TJ; Fayad LE; Lennon PA; Hu P; Garcia M; Routbort MJ; Miranda R; Wang X; Qiao W; Medeiros LJ
    Cancer; 2012 Mar; 118(6):1566-73. PubMed ID: 21882178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.
    Lim ST; Karim R; Nathwani BN; Tulpule A; Espina B; Levine AM
    J Clin Oncol; 2005 Jul; 23(19):4430-8. PubMed ID: 15883411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma in a Korean child.
    Ahn JY; Seo YH; Park PW; Kim KH; Park MJ; Jeong JH; Park SH; Song YH
    Ann Lab Med; 2012 Mar; 32(2):162-6. PubMed ID: 22389885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B cell lymphoma unclassifiable with features intermediate between diffuse large B cell and burkitt lymphoma--presented with multiple lymphomatous polyposis of gastrointestinal tract.
    Jain D; Agrawal S; Chopra P
    J Gastrointest Cancer; 2011 Dec; 42(4):282-6. PubMed ID: 21213068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adding rituximab to CODOX-M/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy.
    Alwan F; He A; Montoto S; Kassam S; Mee M; Burns F; Edwards S; Wilson A; Tenant-Flowers M; Marcus R; Ardeshna KM; Bower M; Cwynarski K
    AIDS; 2015 May; 29(8):903-10. PubMed ID: 25730506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens.
    Carey CD; Gusenleitner D; Chapuy B; Kovach AE; Kluk MJ; Sun HH; Crossland RE; Bacon CM; Rand V; Dal Cin P; Le LP; Neuberg D; Sohani AR; Shipp MA; Monti S; Rodig SJ
    J Mol Diagn; 2015 Jan; 17(1):19-30. PubMed ID: 25468432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations].
    Luo DL; Liu YH; Zhang F; Xu FP; Yan LX; Chen J; Xu J; Luo XL; Zhuang HG
    Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):584-8. PubMed ID: 24314242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.
    Landsburg DJ; Petrich AM; Abramson JS; Sohani AR; Press O; Cassaday R; Chavez JC; Song K; Zelenetz AD; Gandhi M; Shah N; Fenske TS; Jaso J; Medeiros LJ; Yang DT; Nabhan C
    Cancer; 2016 Feb; 122(4):559-64. PubMed ID: 26565895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.